Format

Send to

Choose Destination
  • This is a preview / test site. Please update your PubMed URL to pubmed.gov.
See comment in PubMed Commons below
ACS Med Chem Lett. 2017 Sep 8;8(10):1077-1082. doi: 10.1021/acsmedchemlett.7b00283. eCollection 2017.

Discovery of Novel 5-(Piperazine-1-carbonyl)pyridin-2(1H)-one Derivatives as Orally eIF4A3-Selective Inhibitors.

Author information

  • 1Research, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa 251-8555, Japan.

Abstract

Starting from our previous eIF4A3-selective inhibitor 1a, a novel series of (piperazine-1-carbonyl)pyridin-2(1H)-one derivatives was designed, synthesized, and evaluated for identification of orally bioavailable probe molecules. Compounds 1o and 1q showed improved physicochemical and ADMET profiles, while maintaining potent and subtype-selective eIF4A3 inhibitory potency. In accord with their promising PK profiles and results from initial in vivo PD studies, compounds 1o and 1q showed antitumor efficacy with T/C values of 54% and 29%, respectively, without severe body weight loss. Thus, our novel series of compounds represents promising probe molecules for the in vivo pharmacological study of selective eIF4A3 inhibition.

KEYWORDS:

Eukaryotic initiation factor 4A3 (eIF4A3) inhibitor; P-gp substrate; RNA helicase; metabolic stability; pyridin-2(1H)-one derivative; solubility

PMID:
29057054
PMCID:
PMC5642020
[Available on 2018-10-12]
DOI:
10.1021/acsmedchemlett.7b00283
[PubMed]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society
    Loading ...
    Support Center